A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial.
Shang X, Xie Y, Yu J, Zhang C, Zhao G, Liang F, Liu L, Zhang W, Li R, Yu W, Yue J, Chen C, Duan X, Ma Z, Chen Z, Xiong Y, Yang F, Xiao J, Zhang R, Liu P, Cheng Y, Cao F, Guo F, Liu G, Meng B, Zhou D, Sun Y, Ren X, Yu J, Hao J, Jiang H.
Shang X, et al. Among authors: liang f.
Cancer Cell. 2024 Oct 14;42(10):1747-1763.e7. doi: 10.1016/j.ccell.2024.09.008.
Cancer Cell. 2024.
PMID: 39406186
Clinical Trial.